Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks
After a rocky start to the spring, Wall Street came roaring back in May. President Trump’s softened tariff stance reignited demand for risk assets, triggering the market’s biggest monthly rally since November 2023. The S&P 500 rose ~6%, nudging back into positive territory for the year. Encouraged by this rebound, John Stoltzfus, chief investment strategist at Oppenheimer, has taken the measure of the markets and holds a positive outlook for the near- to mid-term. “The effects of the stock marke
Article Link
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
HOUSTON, May 27, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical t
Article Link
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
HOUSTON, May 20, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 – 5, 2025, in New York, N
Article Link
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
HOUSTON, May 13, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.
Article Link
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
HOUSTON, May 06, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that an abstract will be presented at the American Thoracic Society 2025 Annual Conference, which is being held May 16-21 in San Francisco.
Article Link
|